FR2444713B1 - - Google Patents

Info

Publication number
FR2444713B1
FR2444713B1 FR7835588A FR7835588A FR2444713B1 FR 2444713 B1 FR2444713 B1 FR 2444713B1 FR 7835588 A FR7835588 A FR 7835588A FR 7835588 A FR7835588 A FR 7835588A FR 2444713 B1 FR2444713 B1 FR 2444713B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7835588A
Other languages
French (fr)
Other versions
FR2444713A1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Priority to FR7835588A priority Critical patent/FR2444713A1/en
Priority to CH1099879A priority patent/CH646456A5/en
Priority to OA56977A priority patent/OA06416A/en
Priority to GB7943491A priority patent/GB2034323B/en
Priority to DE19792950995 priority patent/DE2950995A1/en
Priority to BE2/58277A priority patent/BE880670A/en
Publication of FR2444713A1 publication Critical patent/FR2444713A1/en
Application granted granted Critical
Publication of FR2444713B1 publication Critical patent/FR2444713B1/fr
Priority to US08/347,162 priority patent/US6225458B1/en
Priority to US08/369,998 priority patent/US6096879A/en
Priority to US08/478,853 priority patent/US6416996B1/en
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR7835588A 1978-12-18 1978-12-18 PROCESS FOR PRODUCING DNA COMPRISING THE GENOME OF HEPATITIS B VIRUS AND VECTOR COMPRISING SAME Granted FR2444713A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR7835588A FR2444713A1 (en) 1978-12-18 1978-12-18 PROCESS FOR PRODUCING DNA COMPRISING THE GENOME OF HEPATITIS B VIRUS AND VECTOR COMPRISING SAME
CH1099879A CH646456A5 (en) 1978-12-18 1979-12-12 METHOD FOR PRODUCING DNA COMPRISING THE GENOME OF HEPATITIS B VIRUS AND VECTOR COMPRISING SAME
GB7943491A GB2034323B (en) 1978-12-18 1979-12-18 Production of dna comprising the b hepatitis viral genome
DE19792950995 DE2950995A1 (en) 1978-12-18 1979-12-18 METHOD FOR PRODUCING A DNA CONTAINING THE HEPATITIS B VIRUS GENOME AND THE VECTOR CONTAINING THIS GENOME
OA56977A OA06416A (en) 1978-12-18 1979-12-18 A method of producing a DNA comprising the genome of the hepatitis B virus and a vector comprising it.
BE2/58277A BE880670A (en) 1978-12-18 1979-12-18 PROCESS FOR PRODUCING DNA COMPRISING THE GENOME OF HEPATITIS B VIRUS AND VECTOR COMPRISING SAME
US08/347,162 US6225458B1 (en) 1978-12-18 1994-11-23 Process for the production of DNA comprising the genome of the hepatitis B virus and vector including it
US08/369,998 US6096879A (en) 1978-12-18 1995-01-09 Nucleotide sequence comprising the genome of hepatitis B virus, nucleotide sequence coding the surface antigen of the hepatitis B virus, vectors containing the nucleotide sequences, process for the preparation thereof, and antigen obtained thereby
US08/478,853 US6416996B1 (en) 1978-12-18 1995-06-07 Nucleotide sequence comprising the genome of hepatitis b virus, nucleotide sequence coding the surface antigen of the hepatitis b virus, vectors containing the nucleotide sequences, process for the preparation thereof, and antigen obtained thereby

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7835588A FR2444713A1 (en) 1978-12-18 1978-12-18 PROCESS FOR PRODUCING DNA COMPRISING THE GENOME OF HEPATITIS B VIRUS AND VECTOR COMPRISING SAME

Publications (2)

Publication Number Publication Date
FR2444713A1 FR2444713A1 (en) 1980-07-18
FR2444713B1 true FR2444713B1 (en) 1981-02-06

Family

ID=9216265

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7835588A Granted FR2444713A1 (en) 1978-12-18 1978-12-18 PROCESS FOR PRODUCING DNA COMPRISING THE GENOME OF HEPATITIS B VIRUS AND VECTOR COMPRISING SAME

Country Status (6)

Country Link
BE (1) BE880670A (en)
CH (1) CH646456A5 (en)
DE (1) DE2950995A1 (en)
FR (1) FR2444713A1 (en)
GB (1) GB2034323B (en)
OA (1) OA06416A (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480779B2 (en) * 1979-08-30 1986-07-18 Anvar VECTOR CONTAINING A NUCLEOTIDE SEQUENCE OF THE SURFACE ANTIGEN OF HEPATITIS B VIRUS AND METHOD FOR MANUFACTURING AN IMMUNOGENIC MOLECULE USING THE SAME
US6268122B1 (en) 1978-12-22 2001-07-31 Biogen, Inc. Recombinant DNA molecules and their method of production
EP0182442B2 (en) * 1978-12-22 1996-04-03 Biogen, Inc. Recombinant DNA molecules and their method of production
NZ192465A (en) * 1978-12-22 1983-09-30 Biogen Nv Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6835557B1 (en) 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
DE3176404D1 (en) * 1980-04-22 1987-10-08 Pasteur Institut Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
US4393133A (en) * 1980-06-12 1983-07-12 The Wistar Institute Of Anatomy And Biology Human hepatoma derived cell line, process for preparation thereof, and uses therefor
US5145782A (en) * 1980-12-08 1992-09-08 The Regents Of The University Of California DNA expression vector suitable for direct expression of a foreign gene
US4446237A (en) * 1981-03-27 1984-05-01 Life Technologies, Inc. Method for detection of a suspect viral deoxyribonucleic acid in an acellular biological fluid
EP0062286A1 (en) * 1981-03-31 1982-10-13 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic test for hepatitis B virus
US4711955A (en) * 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4769238A (en) 1981-08-04 1988-09-06 The Regents Of The University Of California Synthesis of human virus antigens by yeast
ZW18282A1 (en) 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
AU8746582A (en) * 1981-09-02 1983-03-10 Biogen N.V. Hepatitis b virus e type antigen
FI63596C (en) * 1981-10-16 1983-07-11 Orion Yhtymae Oy MICROBIA DIAGNOSIS FOERFARANDE SOM GRUNDAR SIG PAO SKIKTSHYBRIDISERING AV NUCLEINSYROR OCH VID FOERFARANDET ANVAENDA KOMBINATIONER AV REAGENSER
US4480040A (en) * 1981-12-03 1984-10-30 The United States Of America As Represented By The Secretary Of Agriculture Sensitive and rapid diagnosis of viroid diseases and viruses
JPS5931799A (en) * 1982-08-16 1984-02-20 Science & Tech Agency Recombinant plasmid and preparation of transformed yeast and hepatitis virus b surface antigen using the same
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4820642A (en) * 1983-04-04 1989-04-11 The Regents Of The University Of California Amplified expression vector
FR2560995B1 (en) * 1984-03-07 1988-02-19 Pasteur Institut REAGENTS AND KITS FOR THE QUANTITATIVE DETERMINATION OF A VIRAL NUCLEIC ACID IN A BIOLOGICAL MEDIUM AND METHOD FOR DETERMINING SUCH A VIRAL NUCLEIC ACID
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
WO1993013120A1 (en) * 1991-12-23 1993-07-08 Chiron Corporation Hbv amplifier probes for use in solution phase sandwich hybridization assays
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
CN1370238A (en) 1999-06-16 2002-09-18 艾科斯有限公司 Human poly(ADP-ribose) polymerase 2 materials and methods
WO2002046208A2 (en) 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
EP1883709A4 (en) 2005-04-29 2010-10-13 Univ Rockefeller Human micrornas and methods for inhibiting same
EP2301535B1 (en) 2005-09-01 2014-05-28 Celgene Corporation Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
EP2173378B1 (en) 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
WO2010017248A2 (en) 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
EP2389443B1 (en) 2009-01-23 2018-11-14 Roger Williams Hospital Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
US9216189B2 (en) 2010-01-25 2015-12-22 Icahn School Of Medicine At Mount Sinai Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2863600A1 (en) 2012-02-16 2013-08-22 The Penn State Research Foundation Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
CA2888896A1 (en) 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
JP6655061B2 (en) 2014-07-29 2020-02-26 ノバルティス アーゲー IL-15 and IL-15Ralpha heterodimer dose escalation regimens for treating conditions
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
WO2016069912A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules in vitro and in vivo
EP3851120A4 (en) 2018-09-11 2022-04-27 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
US11786592B2 (en) 2021-05-19 2023-10-17 The University Of Hong Kong Compositions of cardiolipin adjuvants and methods of use thereof
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
US20230364227A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521032A (en) * 1974-08-08 1978-08-09 Ici Ltd Biological treatment
DE2712615A1 (en) * 1977-03-18 1978-09-21 Max Planck Gesellschaft PROCESS FOR MANUFACTURING FILAMENTOES PHAGEN AS A VECTOR FOR SYNTHETIC RECOMBINATES

Also Published As

Publication number Publication date
GB2034323B (en) 1983-01-12
BE880670A (en) 1980-06-18
FR2444713A1 (en) 1980-07-18
DE2950995A1 (en) 1980-07-24
DE2950995C2 (en) 1991-05-02
CH646456A5 (en) 1984-11-30
GB2034323A (en) 1980-06-04
OA06416A (en) 1981-09-30

Similar Documents

Publication Publication Date Title
FR2413106B1 (en)
DE2810586C2 (en)
FR2415528B1 (en)
FR2414140B3 (en)
DE2824024C2 (en)
DE2854710C2 (en)
DE2817949C2 (en)
FR2415446B1 (en)
DE2837970C2 (en)
AU3803078A (en)
DK142649C (en)
DK132178A (en)
AU3892778A (en)
AU73950S (en)
BG25849A1 (en)
BG26022A1 (en)
BG25872A1 (en)
BG25871A1 (en)
BG25858A1 (en)
BG25875A1 (en)
BG25857A1 (en)
BG25854A1 (en)
BG25879A1 (en)
BG25889A1 (en)
BG25843A1 (en)